Fundamental Analysis of AKANDA CORP(NASDAQ:AKAN) stock

Fundamental Rating

Taking everything into account, AKAN scores 1 out of 10 in our fundamental rating. AKAN was compared to 193 industry peers in the Pharmaceuticals industry. AKAN has a bad profitability rating. Also its financial health evaluation is rather negative. AKAN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

AKAN had negative earnings in the past year.

AKAN had a negative operating cash flow in the past year.

1.2 Ratios

With a Return On Assets value of -323.87%, AKAN is not doing good in the industry: 94.24% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -706.22%, AKAN is doing worse than 82.20% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-323.87%
ROE	-706.22%
ROIC	N/A

ROA(3y)-165.35%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of AKAN (11.64%) is comparable to the rest of the industry.

The Profit Margin and Operating Margin are not available for AKAN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	11.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AKAN does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, AKAN has more shares outstanding

AKAN has a worse debt/assets ratio than last year.

2.2 Solvency

AKAN has an Altman-Z score of -10.50. This is a bad value and indicates that AKAN is not financially healthy and even has some risk of bankruptcy.

AKAN has a Altman-Z score of -10.50. This is in the lower half of the industry: AKAN underperforms 75.92% of its industry peers.

A Debt/Equity ratio of 0.08 indicates that AKAN is not too dependend on debt financing.

The Debt to Equity ratio of AKAN (0.08) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-10.5

ROIC/WACCN/A

WACC6.35%

2.3 Liquidity

AKAN has a Current Ratio of 1.41. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.41, AKAN is not doing good in the industry: 75.39% of the companies in the same industry are doing better.

A Quick Ratio of 1.41 indicates that AKAN should not have too much problems paying its short term obligations.

AKAN has a Quick ratio of 1.41. This is in the lower half of the industry: AKAN underperforms 67.02% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.41
Quick Ratio	1.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AKAN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -83.91%.

The Revenue for AKAN has decreased by -17.54% in the past year. This is quite bad

EPS 1Y (TTM)-83.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%95.13%

Revenue 1Y (TTM)-17.54%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%270.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKAN. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AKAN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AKANDA CORP

NASDAQ:AKAN (12/20/2024, 8:00:00 PM)

After market: 1.4 -0.01 (-0.71%)

1.41

+0.05 (+3.68%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-01 2022-11-01/bmo

Earnings (Next)12-13 2022-12-13/bmo

Inst Owners0.49%

Inst Owner Change-100%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.57M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short Ratio0.11

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.72
P/FCF	N/A
P/OCF	N/A
P/B	0.34
P/tB	0.34
EV/EBITDA	N/A

EPS(TTM)-286.63

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-4.08

FCFYN/A

OCF(TTM)-2.87

OCFYN/A

SpS1.95

BVpS4.12

TBVpS4.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-323.87%
ROE	-706.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	11.64%
FCFM	N/A

ROA(3y)-165.35%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.22

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	53.76%
Cap/Sales	62.2%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.41
Quick Ratio	1.41
Altman-Z	-10.5

F-Score4

WACC6.35%

ROIC/WACCN/A

Cap/Depr(3y)72.05%

Cap/Depr(5y)N/A

Cap/Sales(3y)478.34%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-83.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%95.13%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-17.54%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%270.52%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y53.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y88.06%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y86.92%

OCF growth 3YN/A

OCF growth 5YN/A

AKANDA CORP (AKAN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens